Company intelligence / Profile preview

Kairos Pharma Ltd.

Los Angeles, California, USAkairospharma.com ↗

Ownership: Public · KAPA
Development stage: Other

Overview

Kairos Pharma's lead program, ENV105, targets CD105 to reverse drug resistance in multiple cancers. ENV105 has reached Phase 2 trials for castrate-resistant prostate cancer and Phase 1 for EGFR-dependent non-small cell lung cancer. Early preclinical data on additional assets show promise in melanoma and glioblastoma models. Initial safety and interim efficacy results are expected in mid-to-late 2025[4][5][6].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesPeptide inhibitorsImmuno-oncology agents
Industry: Biotech

Drug pipeline

10 assets

carotuximab

9 more assets in the full pipeline.

Partnerships

PreCheck Health Servicesmajor medical centers including Cedars Sinai Hospital, University of Utah, City of Hope Cancer Center[4][5]

Financials

Market cap: $1.5M
Total revenue: $0
Enterprise value: $-1.1M

Beyond the preview

Go deeper on Kairos Pharma Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kairos Pharma Ltd..